08-20-03

9 7003 EU Under the Paperwork Redu	action Act of 1995, no per	sons are r	U.S. Patent and 1 equired to respond to a collect	Frademark C	for use through 04/30/2003. OMB 0651-0031 Office: U.S. DEPARTMENT OF COMMERCE ation unless it displays a valid OMB control number.	
		Applic	ation Number	09/805,	293	
TRANSMITTAL FORM			Filing Date		2, 2001	
			First Named Inventor		Halsted, Charles H.	
(to be used for all correspondence after initial filing)		Art Ur	Art Unit		1634	
, and a second period of the second s			Examiner Name		Souaya, Jehanne E.	
Total Number of Pages in This Submission 4			ey Docket Number		-111710US	
	FNC		S (Check all that appl			
Fee Transmittal Form	☐ Drawin		.o (Check all that appr		Allowance Communication to Group	
		ng-related Papers		Appe	eal Communication to Board of Appeals	
Amendment/Reply Petition		1			eal Communication to Group (Appeal	
		a to Convert to a onal Application		Prop.	rietary Information	
		of Attorney, Revocation ge of Correspondence Address		☐ Statu	is Letter	
Extension of Time Request		minal Disclaimer		Othe	er Enclosure(s) se identify below):	
Express Abandonment Request		Request for Refund CD, Number of CD(s)		Return P	ostcard; copy of references	
☐ Information Disclosure Statement			. ,			
Certified Copy of Priority Document(s) Rem		rks	The Commissioner is authorized to charge any additional fees to Dep Account 20-1430.		to charge any additional fees to Deposit	
Response to Missing Parts/ Incomplete Application			J			
Response to Missing Part under 37 CFR 1.52 or 1.5						
	SIGNATURE O	F APPL	ICANT, ATTORNEY	OR AGE	NT	
Firm Townsend	and Townsend and					
or Individual Laurence	or Laurence I Hyman Reg. No. 35 551					
Signature Convence						
Date August (/9), 2003						
		ERTIFI	CATE OF MAILING			
Express Mail Label: EV 3)0 I hereby certify that this correspon Address" service under 37 CFR 1 Commissioner for Patents, P.O. B	1856951 VS dence is being depo 10 on this date	sited with	n the United States Post and is addressed to:	al Service v	with "Express Mail Post Office to	
Typed or printed name Patric	ia Andrews					
Signature	ton Cir	w		Date	August (19), 2003	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

"Express Mail" Label No. <u>EV 330 856 951 US</u>
Date of Deposit <u>Aug. J. G., 2003</u>

Attorney Docket No.: 02307O-111710US Client Reference No.: 2000-254-1

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HALSTED and DEVLIN

Application No.: 09/805,293

Filed: March 12, 2001

For: MUTATIONS IN HUMAN GLUTAMATE CARBOXYPEPTIDASE II GENE IMPACTING FOLATE METABOLISM, AND DETECTION OF AFFECTED INDIVIDUALS Examiner: Souaya, Jehanne E.

Art Unit: 1634

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

HALSTED and DEVLIN Application No.: 09/805,293

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Ladrence J. Hymar Reg. No. 35,551

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300

MTD:mtd 60020498 v1

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paper , no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

Complete if Known **Application Number** 09/805,293 **Filing Date** March 12, 2001 **First Named Inventor** Halsted, Charles H., et. al. Art Unit 1634 **Examiner Name** Souaya, Jehanne E.

(use as many sheets as necessary)

Page Attorney Docket Number 02307O-111710US

,	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1						
6	AA/	Luthi-Carter et al., "Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II", <i>PNAS</i> 95: 3215-3220 (1998).					
7	AB /	Clarke et al., "Folate, Vitamin B ₁₂ and Serum Total Homocysteini Levels in Confirmed Alzheimer Disease", <i>Arch Neurol.</i> 55: 1449-1455 (1998).					
ı	AC /	Devlin et al., "Molecular Studies of Human Intestinal Folylpoly-Glutamate Carboxypeptidase", <i>Gastroenterology</i> 116: A874 (1999).					
4	AD (Israeli et al., "Molecular Cloning of a Complementary DNA Encoding a Prostate-specific Membrane Antigen", Cancer Res. 53: 227-230 (1993).					
6	AE	Luthi-Carter et al., "Molecular Characterization of Human Brain N-Acetylated <i>α</i> -Linked Acidic Dipeptidase (NAALADase)", <i>J. Pharm. Exper. Therap.</i> 286: 1020-1025 (1998).					
15	AF (O'Keefe et al., "Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene", <i>Biochim. Biophys. Acta</i> 1443: 113-127 (1998).					
6	AG (Rawlings et al., "Structure of membrane glutamate carboxypeptidase", <i>Biochim. Biophys Acta</i> 1139: 247-252 (1997).					
3	AH /	Su et al., ""Alternatively Spliced Variants of Prostate-specific Membrane Antigen RNA: Ratio of Expression as a Potential Measurement of Progression", <i>Cancer Res.</i> 55: 1441-1443 (1995).					

Examiner	Date	•
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.